1. Yang H, Park H, Ryu HJ, Heo J, Kim JS, Oh YL, et al. Frequency of TERT promoter mutations in real-world analysis of 2,092 thyroid carcinoma patients. Endocrinol Metab (Seoul). 2022; 37:652–63.
2. Kim SY, Kim T, Kim K, Bae JS, Kim JS, Jung CK. Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans. J Pathol Transl Med. 2020; 54:310–7.
Article
3. Choi YS, Choi SW, Yi JW. Prospective analysis of TERT promoter mutations in papillary thyroid carcinoma at a single institution. J Clin Med. 2021; 10:2179.
Article
4. Lee J, Ha EJ, Roh J, Kim HK. Presence of TERT±BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma. Surgery. 2021; 170:743–7.
5. Bae JS, Kim Y, Jeon S, Kim SH, Kim TJ, Lee S, et al. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Diagn Pathol. 2016; 11:21.
Article